Subscribe to Search results

Cutter created a task force to try to solve "the hepatitis problem".

Published on:

Behringwerke conducted experiments in heat treatment and began clinical trials.

Published on:

Hyland experimented with dry heat approach.

Published on:

Behringwerke presented its heat-treated process at the Bonn Conference.

Published on:

PFC started performing experiments on pasteurisation.

Published on:

Alpha assessed it had the "nucleus of a process that needs about three or four months' work", and applied for a FDA licence for heat-treated product in January 1983.

Published on:

BPL started development work on a heat-treated 'Hepatitis-Safe' Factor 8 product.

Published on:

FDA licensed Hyland's dry heat-treated product.

Published on:

FDA licensed Armour's heat-treated product, followed by Alpha's and Cutter's products in February 1984.

Published on:

Haemophilia centres at Sheffield, St Thomas', Middlesex and Margate started to use heat-treated concentrates.

Published on:

PFC issued heat-treated Factor 8 for routine use.

Published on:

There was a meeting at Elstree of reference centre directors and others to devise treatment recommendations.

Published on:

Commercial heat-treated concentrates were licensed in UK.

Published on:

BPL released first batches of 8Y for clinical trial.

Published on:

All Factor 8 issued by BPL heat-treated by this date.

Published on:

Only 8Y was issued after this date.

Published on:

BPL and PFL heat-treated F9 became routinely available.

Published on:

Armour withdrew heat-treated Factorate following seroconversions.

Published on:

First formal meeting of haemophilia centre directors took place.

Published on:

Dr Craske reported to the UK Haemophilia Centre Directors ("UKHCDO") hepatitis outbreak in Bournemouth linked to commercial Factor 8.

Published on: